Advertisement
Advertisement
U.S. markets close in 5 hours 3 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Evotec SE (EVT.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
25.56+0.53 (+2.12%)
As of 10:32AM CEST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close25.03
Open25.79
Bid24.99 x 400000
Ask25.04 x 400000
Day's Range25.56 - 25.79
52 Week Range20.25 - 45.70
Volume750
Avg. Volume2,166
Market Cap4.575B
Beta (5Y Monthly)0.98
PE Ratio (TTM)48.41
EPS (TTM)0.53
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.58
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for EVT.F

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • ACCESSWIRE

      Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology

      (ALM), a global biopharmaceutical company focused on skin health, announced today a multi-target alliance in Medical Dermatology. The companies aim to discover and develop novel therapeutics for severe skin diseases, including immune-mediated inflammatory conditions such as atopic dermatitis and non-melanoma skin cancer such as basal cell carcinoma.

    • Benzinga

      Sernova, Evotec Join Forces To Develop 'Functional Cure' For Diabetes

      Sernova Corp and Evotec SE (NASDAQ: EVO) have announced an exclusive global strategic partnership to develop cell therapy treatment for insulin-dependent diabetes. The companies will leverage their respective technologies and scientific expertise to develop an implantable iPSC-based (induced pluripotent stem cells) beta cell replacement therapy. The partnership provides Sernova a global exclusive option to license Evotec's iPSC-based beta cells to treat both type 1 and type 2 diabetes. Also Read

    • GlobeNewswire

      Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a ‘Functional Cure’ for Diabetes

      Partnership Leverages Sernova’s Proprietary Cell Pouch System™ with Evotec’s iPSC-Based Insulin-Producing Beta CellsPartners to Develop and Commercialize an Off-The-Shelf Cell Replacement Therapy for Treatment of Patients with Insulin-Dependent DiabetesEvotec to Make Strategic Equity Investment of CAD $27 M / €20 M in SernovaSernova / Evotec Joint Conference Call and Webcast at 8:30 am EDT May 17, 2022 LONDON, Ontario, May 17, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/X

    Advertisement
    Advertisement